BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
From School Dropout to Example of overcoming adversity: My Excursion - 2Sixteen Kenyans missing in Russia after army recruitment
- 3Katz alleges Army Radio workers misled High Court in bid to halt closure
- 4Portugal among EU countries with the most people working close to 50 hours a week
- 5What are parents to do as doctors clash with Trump administration over vaccines?
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Exploring Asia’s Realm of Flying Snakes
- Fundamental Home Machines for Improved Solace in Summer
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- Australians told to continue Easter travel plans despite fuel shortages
- Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
